Cvetinovic, Natasa (55340266600)Natasa (55340266600)CvetinovicLoncar, Goran (55427750700)Goran (55427750700)LoncarFarkas, Jerneja (25225081600)Jerneja (25225081600)Farkas2025-06-122025-06-122016https://doi.org/10.1007/s00508-016-1138-yhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85000842774&doi=10.1007%2fs00508-016-1138-y&partnerID=40&md5=c0a9e5b60bf2f3027d0d02d7380dfc37https://remedy.med.bg.ac.rs/handle/123456789/7362Heart failure (HF) is a rapidly growing public health problem and the leading cause of morbidity, mortality, and hospitalization in populations > 65 years. The elderly HF patients have an increased prevalence of HF with preserved ejection fraction and comorbidities, may present with atypical symptoms and signs, have a higher risk for adverse drug reactions, and worse prognosis as compared with younger patients. Moreover, there is a lack of evidence-based therapies for this population because they are underrepresented in the clinical trials. The elderly are less likely to be evaluated by a cardiologist and to be treated in accordance with recommendations of the current HF guidelines. Although the treatment is improving, it is still suboptimal; therefore, HF in elderly patients requires mobilization of public health services and improvement of treatment strategies. © 2016, Springer-Verlag Wien.ElderlyHeart failurePublic healthTreatment strategy